The Food and Drug Administration has issued a new warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, due to the occurrence of some secondary blood cancers following treatment. Oncologists and CAR-T experts believe this label update will not change anything about the use of Carvykti and that physicians already have discussions with patients about secondary malignancies due to other cancer therapies. The label means that physicians will have to talk about secondary malignancy risks with patients getting Carvykti. Saad Usmani, a myeloma physician and cell therapist, believes this change will not affect patient care.
Source link
Carvykti CAR-T gets warning label
